Success Metrics

Clinical Success Rate
42.9%

Based on 3 completed trials

Completion Rate
43%(3/7)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
4(57%)

Phase Distribution

Ph phase_2
1
14%
Ph phase_3
3
43%
Ph phase_1
3
43%

Phase Distribution

3

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
3(42.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

42.9%

3 of 7 finished

Non-Completion Rate

57.1%

4 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(3)
Terminated(4)

Detailed Status

Terminated4
Completed3

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
42.9%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (42.9%)
Phase 21 (14.3%)
Phase 33 (42.9%)

Trials by Status

terminated457%
completed343%

Recent Activity

Clinical Trials (7)

Drug Details

Intervention Type
DRUG
Total Trials
7